tradmap

STXS Stereotaxis, Inc.

$0.88 +2.76%

Data as of close

Healthcare · Electromedical & Electrotherapeutic Apparatus

Stereotaxis, Inc. (STXS) is a healthcare company in the Electromedical & Electrotherapeutic Apparatus industry, with a market capitalization of $88 million. Shares last traded at $0.88, 69.7% below their 52-week high. Over the past year the stock is down 69.9%. Net profit margin is -74.2%, below the peer median of -10.0%. Revenue grew 20.3% year over year.

Market Cap
$88M
Shares Out
100.2M
EPS (TTM)
-$0.24
P/E (TTM)*
—
P/S Ratio
2.93
P/B Ratio
7.20
Dividend / Share
—
Dividend Yield
—
52-Week High
$2.90
52-Week Low
$0.82
Volume (venue)
8,592
Avg Vol (3m, venue)
29,539.571

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
-11.95%
1M
-25.42%
3M
-38.24%
6M
-53.43%
YTD
-61.65%
1Y
-69.86%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
26.98
SMA (50)
$1.21
SMA (200)
$1.70
Price vs SMA50
-27.18%
Price vs SMA200
-48.28%
ATR (14)
$0.06

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$30M
Net Income
-$22M
Gross Margin
55.6%
Operating Margin
-75.7%
Net Margin
-74.2%
Return on Equity
-182.3%
Return on Assets
-40.2%
Current Ratio
1.42
Debt / Equity
0.02
Revenue Growth (YoY)
+20.3%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 -$0.05 2026-08-12
Q1 2026 -$0.06 2026-05-13
Q4 2025 (derived) -$0.06 2026-03-12
FY 2025 -$0.25 2026-03-12
Q3 2025 -$0.07 2025-11-12
Q2 2025 -$0.05 2025-08-13

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Electromedical & Electrotherapeutic Apparatus peers

STXS vs 14 industry peers (Electromedical & Electrotherapeutic Apparatus), by market cap. Data as of close

P/S vs peers
2.93 / 2.65 med
+11% premium
Net margin vs peers
-74.2% / -10.0% med
below median
1–14 of 14
MDTMedtronic$127.0B24.283.3813.9%+2.86%
LIVNLivanova Plc$4.4B23.443.0012.8%+1.58%
ITGRInteger Holdings Corp$4.3B41.502.365.7%-0.02%
AXGNAxogen, Inc.$3.0B—11.16-12.0%+0.97%
TMDXTransmedics Group, Inc.$2.3B15.213.4522.7%+1.05%
CNMDConmed Corp$1.4B29.481.013.4%+5.20%
CBLLCeribell, Inc.$1.0B—10.15-64.7%+1.51%
INMDInmode Ltd.$867M9.242.3425.3%+3.56%
CVCapsoVision, Inc$337M———-1.32%
ELMDElectromed, Inc.$224M19.853.0415.3%-0.28%
FOCLEDAP TMS SA$161M—2.29-41.5%+2.26%
VANIVivani Medical, Inc.$99M—207.94—+0.00%
STXSStereotaxis, Inc.$88M—2.93-74.2%+2.76%
NRXSNeuraxis, INC$84M———-6.91%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.